An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Buxton Helmsley Publicly Responds to Departure of Mallinckrodt Plc. CCO, After Open Letter to U.S. SEC Detailing Accounting Fraud
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Negative)
Tags
NEW YORK--(BUSINESS WIRE)--
The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with significant holdings of Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (OTC: MNKKQ) common stock, and with the backing of other various shareholders, today issued an open letter responding to the departure of the Company’s Chief Communications Officer, Ms. Brandi Robinson.
The Company’s Senior Vice President of Finance, Ms. Kathy Schaefer, resigned on November 3, 2021, just days after an October 26, 2021, open letter to the Chairman and Commissioners of the U.S. Securities and Exchange Commission outlining/detailing numerous instances of fraud at the Company, including accounting fraud, bankruptcy fraud, electoral fraud, proxy fraud, and insider trading on undisclosed information by the Company’s board of directors and management.
BHG also publicly responded to Ms. Schaefer’s resignation on November 5, 2021, in an open letter, which may also be found at the link below.
The full open letter to the Company’s board of directors, in response to Ms. Robinson’s departure, may be found at (along with all previous letters): http://www.revivemallinckrodt.com/
Members of the Mallinckrodt Plc. Board of Directors:Mark C. Trudeau, Angus Russell, Anne C. Whitaker, Joann A. Reed, Carlos V. Paya (M.D., Ph.D.), J. Martin Carroll, Paul R. Carter, David Norton, Kneeland Youngblood, and David Carlucci.
About Buxton Helmsley:The Buxton Helmsley Group, Inc. ("BHG") is a premier financial service, asset management and securities research firm, providing an array of services to a diversified group of individuals, corporations, trusts and other entities. The firm is headquartered in New York City.
Mallinckrodt Pharmaceuticals is an Irish–tax registered manufacturer of specialty pharmaceuticals , generic drugs and imaging agents. In 2017 it generated 90% of sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S. Mallinckrodt's 2013 tax inversion to Ireland drew controversy when it was shown Acthar, was Medicaid's most expensive drug. Mallinckrodt acquires , manufactures, and distributes products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the acquisition, manufacture, and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products, and radiopharmaceuticals. The company employed 5,500 and had net sales of $3.2 billion in 2017; of which $2.9 billion was from the U.S. healthcare system.
